SAVAInvestor•globenewswire•
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Sentiment:Negative (20)
Summary
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 25, 2025 by globenewswire